SCHEMBL981219

SCHEMBL981219

CC(C)[Si](Oc1ccc(I)cc1Cl)(C(C)C)C(C)C

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 1/20 0.35
MAPK1 P28482 2/20 0.35
CSNK2A1 P68400 2/20 0.33
S1PR4 O95977 1/20 0.32
LMNA P02545 1/20 0.31
TSHR P16473 1/20 0.31
ADRA2A P08913 1/20 0.31
ADRA2B P18089 1/20 0.31
S1PR1 P21453 1/20 0.31
S1PR3 Q99500 1/20 0.31
RORC P51449 1/20 0.30
POLB P06746 1/20 0.30
CYP1A2 P05177 1/20 0.30
GLA P06280 1/20 0.30
CYP3A4 P08684 1/20 0.30
CYP2D6 P10635 1/20 0.30
CYP2C9 P11712 1/20 0.30
HPGD P15428 1/20 0.30
ALOX12 P18054 1/20 0.30
CYP2C19 P33261 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL34467555 0.86 ALDH1A1 (0.33) IDO1
SCHEMBL5604866 0.81 MAPK1 (0.50) MAPK1S1PR4LMNATSHRPOLB
SCHEMBL15298777 0.80 ACHE (0.41) MAPK1CSNK2A1POLBCYP1A2CYP3A4
SCHEMBL1878091 0.80
SCHEMBL2429174 0.79 TSHR (0.47) MAPK1S1PR4LMNATSHRHPGD
SCHEMBL30888341 0.79 SLC6A4 (0.40) HPGD
SCHEMBL26386327 0.76 CSNK2A1 (0.56) IDO1MAPK1CSNK2A1LMNAS1PR1
SCHEMBL15280183 0.75 MAPT (0.37) MAPK1POLBCYP1A2CYP3A4CYP2C9
SCHEMBL2424549 0.75 MAPK1 (0.33) MAPK1CSNK2A1
SCHEMBL16279927 0.75 SLC6A4 (0.50)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190201404-A1 THIENOPYRIMIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SERVIER LAB (FR) 2019-07-04 US disclosed
US-10278972-B2 Thienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them LES LABORATOIRES SERVIER (FR) 2019-05-07 US disclosed
US-20170216293-A1 THIENOPYRIMIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM LES LABORATOIRES SERVIER (FR) 2017-08-03 US disclosed
US-9670227-B2 Thienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them LES LABORATOIRES SERVIER (FR) 2017-06-06 US disclosed
EP-2886545-B1 New thienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them SERVIER LAB (FR) 2016-06-29 EP disclosed
WO-2015097123-A1 NEW THIENOPYRIMIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM LES LABORATOIRES SERVIER (FR) 2015-07-02 WO disclosed
US-20150175623-A1 THIENOPYRIMIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM LES LABORATOIRES SERVIER (FR) 2015-06-25 US disclosed
EP-2886545-A1 New thienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them Les Laboratoires Servier (FR) 2015-06-24 EP disclosed
EP-2303267-B1 POLYMORPHIC FORM OF A [1, 2, 4] TRIAZOLO [4, 3-A]PYRIDINE DERIVATIVE FOR TREATING INFLAMMATORY DISEASES PFIZER LTD (GB) 2013-07-03 EP disclosed
EP-2303267-B1 POLYMORPHIC FORM OF A [1, 2, 4] TRIAZOLO [4, 3-A]PYRIDINE DERIVATIVE FOR TREATING INFLAMMATORY DISEASES PFIZER LTD (GB) 2013-07-03 EP disclosed
US-8222273-B2 Polymorphic form of a [1,2,4]triazole[4,3-A] pyridine derivative inflammatory diseases PFIZER LIMITED (GB) 2012-07-17 US disclosed
US-8222273-B2 Polymorphic form of a [1,2,4]triazole[4,3-A] pyridine derivative inflammatory diseases PFIZER LIMITED (GB) 2012-07-17 US disclosed
EP-2303267-A2 POLYMORPHIC FORM OF A [1, 2, 4] TRIZOLO [4, 3-A! PYRIDINE DERIVATIVE FOR TREATING INFLAMMATORY DISEASES Pfizer Limited (GB) 2011-04-06 EP disclosed
US-20110003848-A1 Polymorphic Form Of A [1,2,4]Triazole[4,3-A] Pyridine Derivative For Treating Inflammatory Diseases PFIZER LIMITED (GB) 2011-01-06 US disclosed
US-20110003848-A1 Polymorphic Form Of A [1,2,4]Triazole[4,3-A] Pyridine Derivative For Treating Inflammatory Diseases PFIZER LIMITED (GB) 2011-01-06 US disclosed
WO-2009098612-A2 POLYMORPHIC FORM OF A [1, 2, 4] TRIAZOLO [4, 3-A] PYRIDINE DERIVATIVE FOR TREATING INFLAMMATORY DISEASES PFIZER LIMITED (GB) 2009-08-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170216293-A1 THIENOPYRIMIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM TYMS, TYMP, TPX2 IDO1 915/4885MAPK1 3020/4885CSNK2A1 2554/4885
US-10278972-B2 Thienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them TYMS, TYMP, TPX2 IDO1 915/4885MAPK1 3020/4885CSNK2A1 2554/4885
US-20190201404-A1 THIENOPYRIMIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM TYMS, TYMP, TPX2 IDO1 915/4885MAPK1 3020/4885CSNK2A1 2554/4885
US-20150175623-A1 THIENOPYRIMIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM TYMS, TYMP, TPX2 IDO1 915/4885MAPK1 3020/4885CSNK2A1 2554/4885
US-20110003848-A1 Polymorphic Form Of A [1,2,4]Triazole[4,3-A] Pyridine Derivative For Treating Inflammatory Diseases CYP1B1, UBE2V1, CYP4B1 IDO1 486/4885MAPK1 2673/4885CSNK2A1 784/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.